United Therapeutics Corporation and Corsair Pharma Inc. announced that they entered into an exclusive license agreement for Corsair's portfolio of patents covering treprostinil prodrugs as well as an equity investment by United Therapeutics in Corsair. Under the terms of the license agreement, United Therapeutics has been granted an exclusive license to Corsair's intellectual property for the development of treprostinil prodrug formulations. Corsair will continue development of transdermal treprostinil prodrug formulations for PAH. Corsair received upfront consideration, and is entitled to royalty payments based on the commercialization of treprostinil prodrug products by United Therapeutics that are covered by Corsair's patents.